Trial Profile
A Randomized, Open-label Phase III Study of First-line Treatment With Erlotinib Intercalated With Gemcitabine/ Cisplatin or Carboplatin Therapy Versus Erlotinib in Stage IIIB/IV NSCLC Patients With EGFR Mutation
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Dec 2013 New trial record